Skip to main content

Advertisement

SpringerLink
Log in

Pulmonary hypertension: current diagnosis and treatment

  • REVIEW
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Pulmonary hypertension (PH) is a devastating disease that – if untreated – is characterized by a poor prognosis. According to the current classification (Venice, 2003), pulmonary arterial hypertension (PAH) is distinguished from other forms of PH. Recent advances in drug therapy have led to a dramatic improvement of medical care particularly in patients with PAH. Hence, early establishment of the diagnosis appears increasingly important. This review article gives an overview on the definition, classification, pathophysiology, and clinical presentation of various forms of PH. Furthermore, it summarizes the recommended diagnostic work-up and the current treatment options particularly in PAH, with special emphasis on prostanoids, endothelin receptor antagonists (ERAs), and phosphopdiesterase type 5 (PDE5) inhibitors such as sildenafil. Finally, novel developments are being discussed which currently represent an exciting field of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Actelion Pharamceuticals (2006) data on file

  2. American Thoracic Society (2002) ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 166:111–117

    Google Scholar 

  3. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, Mc Laughlin VV, American College of Chest Physicians (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (Suppl 1):35S–62S

    Article  PubMed  Google Scholar 

  4. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434

    PubMed  CAS  Google Scholar 

  5. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galié N, on behalf of the STRIDE-2 Study Group (2006) Treatment of pulmonary arterial hypertension with the selective endothelin – A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049–2056

    Article  PubMed  CAS  Google Scholar 

  6. Barst RJ, Langleben D, Frost A, Horn EM; Oudiz R, Shapiro S, McLaughlin VV; Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441–447

    Article  PubMed  Google Scholar 

  7. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125

    Article  PubMed  CAS  Google Scholar 

  8. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka M, Olschewski H, Gaine SP (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:40S–47S

    Article  PubMed  Google Scholar 

  9. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302

    Article  PubMed  CAS  Google Scholar 

  10. Bossone E, Alvelar E, Bach DS et al (2000) Diagnostic value of resting tricuspid regurgitation velocity and right ventricular ejection flow parameters parameters for the detection of exercise induced pulmonary arterial hypertension. Int J Card Imaging 16:429–436

    Article  PubMed  CAS  Google Scholar 

  11. Bossone E, Bodini BD, Mazza A, Allegra L (2005) Pulmonary arterial hypertension: the key role of echocardiography. Chest 127:1836–1843

    Article  PubMed  Google Scholar 

  12. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF (1999) Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 33:1662–1666

    Article  PubMed  CAS  Google Scholar 

  13. Channick RN, Simmoneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized, placebo-controlled study. Lancet 358:1119–1123

    Article  PubMed  CAS  Google Scholar 

  14. Chaouat A, Bugnet A-S, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189–194

    Article  PubMed  Google Scholar 

  15. Cremers B, Kjelström B, Südkamp M, Böhm M (2002) Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension. Am J Med 112:428–430

    Article  PubMed  Google Scholar 

  16. Currie PJ, Seward JB, Chan KL (1985) Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6:750–756

    PubMed  CAS  Google Scholar 

  17. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343–349

    PubMed  Google Scholar 

  18. Denton C, Cailes J, Phillips G, Wells A, Black C, Du Bois M (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243

    Article  PubMed  CAS  Google Scholar 

  19. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655–31665

    Article  PubMed  CAS  Google Scholar 

  20. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313–1321

    Article  PubMed  CAS  Google Scholar 

  21. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Resp Crit Care Med 174:1034–1041

    Article  PubMed  Google Scholar 

  22. Galié N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502

    Article  PubMed  Google Scholar 

  23. Galié N, Seeger W, Naeije R, Simmoneau G, Rubin RJ (2004a) Comparative analysis of clinical trials and evidence- based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):S81–S88

    Article  Google Scholar 

  24. Galié N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T et al (2004b) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. ESC Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25:2243–2278

    Article  Google Scholar 

  25. Galié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simmoneau G, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157

    Article  PubMed  Google Scholar 

  26. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A et al (2003) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139–1141

    Article  PubMed  Google Scholar 

  27. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360:895–900

    Article  PubMed  CAS  Google Scholar 

  28. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522

    PubMed  CAS  Google Scholar 

  29. Hertz MI, Taylor DO, Trulock EP et al (2002) The registry of the international society for heart and lung transplantation: nineteenth official report 2002. J Heart Lung Transplant 21:950–970

    Article  PubMed  Google Scholar 

  30. Höper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24:1007–1010

    Article  CAS  Google Scholar 

  31. Höper MM, Markevych I, Spiekerkötter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858–863

    Article  Google Scholar 

  32. Höper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E (2003) Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22:330–334

    Article  CAS  Google Scholar 

  33. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004a) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):13S–24S

    Article  CAS  Google Scholar 

  34. Humbert M, Sitbon O, Simonneau G (2004b) Treatment of pulmonary arterial arterial hypertension. N Engl J Med 351:1425–1436

    Article  CAS  Google Scholar 

  35. Kaul S, Tei C, Hopkins JM, Shah PM (1984) Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 107:526–531

    Article  PubMed  CAS  Google Scholar 

  36. Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P (2004) Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):73S–80S

    Article  PubMed  Google Scholar 

  37. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2005) Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension. Chest 127:1647–1653

    Article  PubMed  CAS  Google Scholar 

  38. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90(6):677–680

    Article  PubMed  CAS  Google Scholar 

  39. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ (2007) Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115:59–66

    Article  PubMed  CAS  Google Scholar 

  40. Magnussen H, Geockenjan G, Kohler D, Matthys H, Morr H, Worth H et al (2001) Guidelines to long-term oxygen therapy. Pneumologie 55:454–464

    Article  PubMed  CAS  Google Scholar 

  41. Masuyama T, Kodama K, Kitabatake A, Sato H, Nanto S, Inoue M (1986) Continuous- wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation 74:484–492

    PubMed  CAS  Google Scholar 

  42. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE; American College of Chest Physicians (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence- based clinical practice guidelines. Chest 126(Suppl 1):14S–34S

    Article  PubMed  Google Scholar 

  43. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S; Treprostinil Study Group (2003) Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293–299

    Article  PubMed  CAS  Google Scholar 

  44. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417–1431

    Article  PubMed  Google Scholar 

  45. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Resp Crit Care Med 174:1257–1263

    Article  PubMed  CAS  Google Scholar 

  46. McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482

    Article  PubMed  CAS  Google Scholar 

  47. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galié N, Rainisio M, Simonneau G, Rubin RJ (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244–249

    Article  PubMed  CAS  Google Scholar 

  48. McQuillan BM, Picard MH, Leavitt M, Weymann AE (2001) Clinical correlates and reference intervals for pulmonary artery systolic pressures among echocardiographically normal subjects. Circulation 104:2797–2802

    PubMed  CAS  Google Scholar 

  49. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer J, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FFJ, Wilkens H, Katus HA, Olschewski H, Grünig E (2006) Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114:1482–1489

    Article  PubMed  Google Scholar 

  50. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398–2403

    Article  PubMed  CAS  Google Scholar 

  51. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492

    PubMed  CAS  Google Scholar 

  52. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–870

    PubMed  CAS  Google Scholar 

  53. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB; National Heart, Lung and Blood Institute/ Office of Rare Diseases (2004) Pulmonary arterial hypertension: future directions. Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 109:2947–2952

    Article  PubMed  Google Scholar 

  54. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G (2004) Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43(Suppl S12):33S–39S

    Article  PubMed  CAS  Google Scholar 

  55. Oh JK, Seward JB, Tajik AJ (1999) Pulmonary hypertension. In: Oh JK, Seward JB, Tajik AJ (eds) The Echo Manual. 2nd Edition. Lippincott Williams & Wilkins, Philadelphia, pp 215–222

  56. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Höper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435–443

    PubMed  CAS  Google Scholar 

  57. Olschewski H, Ghofrani HA, Walmrath D, Schermuly RT, Temmesfeld- Wollbrück B, Grimminger F et al (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600–607

    PubMed  CAS  Google Scholar 

  58. Olschewski H, Höper MM, Borst MM, Ewert R, Grünig E, Kleber F-X, Kopp B, Opitz C, Reichenberger F, Schmeisser A, Schranz D, Schulze-Neick I, Wilkens H, Winkler J, Worth H (2007) Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Leitlinien der Deutschen Gesellschaft für Pneumologie, der Deutschen Gesellschaft für Kardiologie und der Deutschen Gesellschaft für Pädiatrische Kardiologie. Clin Res Cardiol (in press)

  59. Olschewski H, Simmoneau G, Galié N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Höper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study Group (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329

    Article  PubMed  CAS  Google Scholar 

  60. Ommen SR, Nishimura RA, Hurrell DG, Klarich KW (2000) Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc 75:24–29

    Article  PubMed  CAS  Google Scholar 

  61. Oudiz RJ (2005) The role of exercise testing in the management of pulmonary arterial hypertension. Sem Respir Crit Care Med 26:379–384

    Article  Google Scholar 

  62. Pengo V, Lensing A, Prins M, Marchiori A, Davidson B, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264

    Article  PubMed  CAS  Google Scholar 

  63. Penning S, Robinson K, Major C, Garite T (2001) A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol 184:1568–1570

    Article  PubMed  CAS  Google Scholar 

  64. Raymond RJ, Hinderliter AL, Willis PW et al (2002) Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39:1214–1219

    Article  PubMed  Google Scholar 

  65. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81

    PubMed  CAS  Google Scholar 

  66. Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151–158

    PubMed  CAS  Google Scholar 

  67. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 139:871–873

    PubMed  Google Scholar 

  68. Rubin LJ, Badesh DB, Barst RJ, Galié N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simmonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  PubMed  CAS  Google Scholar 

  69. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, Palomar A, Gomez A (1998) Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. J Am Coll Cardiol 32:297–304

    Article  PubMed  CAS  Google Scholar 

  70. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43:1149–1153

    Article  PubMed  CAS  Google Scholar 

  71. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE (2002) Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166:314–322

    Article  PubMed  Google Scholar 

  72. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ; Treprostinil Study Group (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804

    PubMed  Google Scholar 

  73. Simonneau G, Galié N, Rubin L, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl 1): 5S–12S

    Article  PubMed  Google Scholar 

  74. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simmoneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111

    Article  PubMed  CAS  Google Scholar 

  75. Tei C, Dujardin KS, Hodge DO et al (1996) Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9:838–847

    Article  PubMed  CAS  Google Scholar 

  76. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzynska L (2003) Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844–848

    Article  PubMed  CAS  Google Scholar 

  77. Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R (2002) Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary exercise testing. Circulation 106:319–324

    Article  PubMed  Google Scholar 

  78. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222

    PubMed  CAS  Google Scholar 

  79. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB (1998) Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81:1157–1161

    Article  PubMed  CAS  Google Scholar 

  80. Zahn R, Zeymer U, Scheidt T, Mark B, Layer G, Senges J (2006) An unusual cause of dyspnea and pulmonary hypertension in a patient with a symptom history of 20 years – “Just do it again”. Clin Res Cardiol 95:68–71

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik III für Innere Medizin, Universität zu Köln, Kerpener Str. 62, 50924, Köln, Germany

    Stephan Rosenkranz

Authors
  1. Stephan Rosenkranz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Rosenkranz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenkranz, S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 96, 527–541 (2007). https://doi.org/10.1007/s00392-007-0526-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-007-0526-8

Key words

Search

Navigation